However, given the high prevalence of mutated RAS genes, targeting RAS or downstream effectors of the MAPK-pathway such as MEK and ERK [41, 42] would be a valuable treatment option for BPDCN. This evidence concerns the gene MAP2K7 and CD4+/CD56+ hematodermic neoplasm.